Position in ENGN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$363,300
-$1,066,800 QoQ
Shares Held
210,000
0.0% QoQ
Ownership
0.313%
of shares outstanding
% of Portfolio
0.09%
of 13F equity value
Holder Rank
#29
of 60 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ENGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Elmind Capital, LP holds $379,440,166 across 31 Biotechnology names. ENGN ranks #31 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | COGT |
Cogent Biosciences, Inc.
|
1,170,740 | $45,307,638 | |
| 2 | SNDX |
Syndax Pharmaceuticals Inc
|
1,855,000 | $40,550,300 | |
| 3 | CLDX |
Celldex Therapeutics, Inc.
|
990,000 | $36,837,900 | |
| 4 | RLAY |
Relay Therapeutics, Inc.
|
1,465,279 | $27,415,370 | |
| 5 | PCVX |
Vaxcyte, Inc.
|
452,340 | $26,294,524 | |
| 6 | VERA |
Vera Therapeutics, Inc.
|
436,518 | $18,730,987 | |
| 7 | PHVS |
Pharvaris N.V.
|
525,750 | $18,180,435 | |
| 8 | VRDN |
Viridian Therapeutics, Inc.\DE
|
984,931 | $18,093,182 |
All Filings in ENGN
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $363,300 | 210,000 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $1,430,100 | 210,000 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $1,896,300 | 210,000 | Shares | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||